This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kemeny, N. Articles by Fong, Y. Search for Related Content PubMed PubMed Citation Articles by Kemeny, N. Articles by Fong, Y. Related Articles Related Correspondence

Phase I/II Study of Hepatic Arterial Therapy With Floxuridine and Dexamethasone in Combination With Intravenous Irinotecan As Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer

From the Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Nancy E. Kemeny, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021.

Purpose: Patients who undergo resection of liver metastases from colorectal cancer have an average 2-year survival of 65%. With hepatic arterial infusion (HAI) plus systemic fluorouracil and leucovorin, 2-year survival increased to 86%. For further improvement in both local and systemic control, combinations of new systemic drugs with HAI are being explored. The purpose of this study was to determine the maximum-tolerated dose (MTD) of systemic irinotecan (CPT-11) and HAI floxuridine (FUDR) plus dexamethasone (DEX) as combination adjuvant therapy after liver resection.

Patients and Methods: Ninety-six patients who underwent complete resection of liver metastases from colorectal cancer were treated with six monthly cycles of HAI FUDR plus DEX for 14 days of each 4-week cycle plus escalating doses of systemic CPT-11. The primary end points of the phase I/II study were the MTD and efficacy of this regimen.

Results: The MTD for combined systemic CPT-11 and HAI FUDR was CPT-11 at 200 mg/m² every other week and FUDR at 0.12 mg/kg x pump volume ÷ pump flow rate. The dose-limiting toxicities were diarrhea and neutropenia. With a median follow-up time of 26 months, the 2-year survival rate is 89%. All of the 27 patients who were treated at the MTD are alive.

Conclusion: In patients who undergo resection of liver metastases from colorectal cancer, adding systemic CPT-11 to HAI therapy in an adjuvant regimen is feasible. This regimen seems to have comparable activity to fluorouracil and leucovorin, but further studies are needed to assess whether it improves local control or decreases extrahepatic recurrences.

Related Correspondence

• Is There a New Drug Beyond Floxuridine for Intra-Arterial Hepatic Chemotherapy in Liver Metastases From Colorectal Cancer?
  G. Fiorentini, S. Rossi, P. Bernardeschi, M. Cantore, and S. Guadagni
  JCO 2005 23: 2105 [Full Text]

This article has been cited by other articles:

				D. G. Power and G. D. Leonard Hepatic Arterial Infusion: A Treatment at the "End of an Era"? J. Clin. Oncol., May 20, 2008; 26(15): 2597 - 2598. [Full Text] [PDF]

				N. Kemeny Presurgical Chemotherapy in Patients Being Considered for Liver Resection Oncologist, July 1, 2007; 12(7): 825 - 839. [Abstract] [Full Text] [PDF]

				G. Portier, D. Elias, O. Bouche, P. Rougier, J.-F. Bosset, J. Saric, J. Belghiti, P. Piedbois, R. Guimbaud, B. Nordlinger, et al. Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial J. Clin. Oncol., November 1, 2006; 24(31): 4976 - 4982. [Abstract] [Full Text] [PDF]

				H. Seki and M. Shiina Placement of a long tapered side-hole catheter in the hepatic artery: technical advantages, catheter stability, and arterial patency. Am. J. Roentgenol., November 1, 2006; 187(5): 1312 - 1320. [Abstract] [Full Text] [PDF]

				N. E. Kemeny, D. Niedzwiecki, D. R. Hollis, H.-J. Lenz, R. S. Warren, M. J. Naughton, J. C. Weeks, E. R. Sigurdson, J. E. Herndon II, C. Zhang, et al. Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481) J. Clin. Oncol., March 20, 2006; 24(9): 1395 - 1403. [Abstract] [Full Text] [PDF]

				M. Ducreux, M. Ychou, A. Laplanche, E. Gamelin, P. Lasser, F. Husseini, F. Quenet, F. Viret, J.-H. Jacob, V. Boige, et al. Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4881 - 4887. [Abstract] [Full Text] [PDF]

				W. D. Ensminger A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases J. Clin. Oncol., August 1, 2005; 23(22): 4815 - 4817. [Full Text] [PDF]

				M. Faynsod, L. D. Wagman, J. Longmate, M. Carroll, and L. A. Leong Improved Hepatic Toxicity Profile of Portal Vein Adjuvant Hepatic Infusional Chemotherapy J. Clin. Oncol., August 1, 2005; 23(22): 4876 - 4880. [Abstract] [Full Text] [PDF]

				G. Fiorentini, S. Rossi, P. Bernardeschi, M. Cantore, and S. Guadagni Is There a New Drug Beyond Floxuridine for Intra-Arterial Hepatic Chemotherapy in Liver Metastases From Colorectal Cancer? J. Clin. Oncol., March 20, 2005; 23(9): 2105 - 2105. [Full Text] [PDF]

				N. E. Kemeny In Reply: J. Clin. Oncol., March 20, 2005; 23(9): 2106 - 2106. [Full Text] [PDF]

				J. Taieb, P. Artru, F. Paye, C. Louvet, N. Perez, T. Andre, B. Gayet, M. Hebbar, F. M. Goebel, C. Tournigand, et al. Intensive Systemic Chemotherapy Combined With Surgery for Metastatic Colorectal Cancer: Results of a Phase II Study J. Clin. Oncol., January 20, 2005; 23(3): 502 - 509. [Abstract] [Full Text] [PDF]